MediLink Therapeutics focuses on developing competitive drug conjugates internationally. With independent intellectual property rights, MediLink Therapeutics develops the next generation of conjugate technologies. The future products will provide better therapeutic windows for the unmet clinical needs. MediLink Therapeutics strives to upgrade technologies, establish diverse technology platforms for drug conjugates, and expand into new disease areas to serve global patients continuously.
| Website | http://www.medilinkthera.com |
| Revenue | $27.4 million |
| Employees | 54 (40 on RocketReach) |
| Address | B3-101, Bio-Industrial Park, 218, Xinghu Street, Suzhou, Jiangsu, CN |
| Industry | Biotechnology Research |
| Keywords | Pharmaceutical Development, Biopharmaceutical, Drug Development, Therapeutic Development, Biotechnology, Next Generation Therapeutics, Innovative Medicines, Advanced Drug Delivery, Pharmaceutical Research, Precision Medicine, Targeted Therapy, Antibody Drug Conjugates, Cancer Therapeutics, Oncology, Clinical Development, Pharmaceutical Manufacturing, Intellectual Property |
| Competitors | Amgen, Vertex Pharmaceuticals, Regeneron, Neurocrine Biosciences, Alnylam Pharmaceuticals, CRISPR Therapeutics, Spark Therapeutics, Inc., bluebird bio, Genzyme Europe B.V., Amicus Therapeutics +32 more (view full list) |
Looking for a particular MediLink Therapeutics employee's phone or email?
MediLink Therapeutics Questions
The MediLink Therapeutics annual revenue was $27.4 million in 2026.
Tongtong Xue is the Founder，Board Chairman and CEO of MediLink Therapeutics.
40 people are employed at MediLink Therapeutics.
MediLink Therapeutics is based in Suzhou, Jiangsu.
Top MediLink Therapeutics Employees
-
55+
-
Craig Kuder
SVP-US General Manager at MediLink Therapeutics
Indianapolis, IN, US23 -
Tianle Redanz
Head of Business Development in US at MediLink Therapeutics
Mountainside, NJ, US21 -
Vivian Liu
Sr. Medical Director at MediLink Therapeutics
Shanghai, China45+
Related Companies
